TGTX - CIK 0001001316
TG THERAPEUTICS, INC. (TGTX) reported revenue of $616.29M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $616.29M | +87.3% |
| FY 2024 | $329.00M | +40.8% |
| FY 2023 | $233.66M | +8290.0% |
| FY 2022 | $2.79M | -58.4% |
| FY 2021 | $6.69M | +4300.7% |
| FY 2020 | $152.00K | +0.0% |
| FY 2019 | $152.00K | +0.0% |
| FY 2018 | $152.00K | +0.0% |
| FY 2017 |
TG THERAPEUTICS, INC. (TGTX) reported revenue of $616.29M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, TG THERAPEUTICS, INC.'s revenue grew from $152.00K to $616.29M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $152.00K |
| +0.0% |
| FY 2016 | $152.00K | - |